دانلود کتاب مدیریت عوارض جانبی درمان سرطان سینه

Breast cancer is the second most common cancer worldwide, accounting for 11.6% of all new can-cer diagnoses after lung cancer [1]. The incidence of breast cancer has steadily risen over the years and is projected to surpass 3.1 million new cases by 2045 [1]. However, this rise is not uniform across geographic regions; developed countries have a higher incidence of breast cancer [2, 3]. Advancements in screening and treatment have led to declining mortality rates in high-income countries. However, there are significant dispari-ties that emphasize the need for targeted inter-ventions and equitable access to care [4]. Breast cancer has a multifactorial etiology that encom-passes hormonal, genetic, dietary, lifestyle, and environmental factors. At least 50% of cases lack identifiable risk factors beyond age and gender. Comprehensive screening and prevention strate-gies are imperative to reduce the burden of breast cancer. Mammography screening programs have shown efficacy in reducing mortality, although implementation and participation rates vary [5]. Personalized surveillance and prevention approaches can be enabled by identifying high- risk individuals through genetic testing and risk assessment models [6, 7]. The treatment of breast cancer requires a multidisciplinary approach that is tailored to the individualized characteristics of a patient and disease stage. Both locoregional management and systemic therapy are essential to minimize the risk of relapse in the early stages. In recurrent or metastatic settings, systemic treat-ments prioritize both survival and quality of life. This necessitates collaborative decision making and integration of supportive care. Addressing the multifaceted challenges posed by breast can-cer requires concerted efforts emphasizing the prevention, early detection, and personalized treatment approaches across healthcare systems.